Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
AstraZeneca
National Institutes of Health Clinical Center (CC)
Kivu Bioscience Inc.
BeOne Medicines
NiKang Therapeutics, Inc.
MacroGenics
SystImmune Inc.
SN BioScience
National Cancer Institute (NCI)
Incyte Corporation
Janux Therapeutics
NiKang Therapeutics, Inc.
Novelty Nobility, Inc.
Pfizer
Hoffmann-La Roche
University of Virginia
Incyte Corporation
National Cancer Institute (NCI)
Sotio Biotech Inc.
Carisma Therapeutics Inc
Vincerx Pharma, Inc.
Xencor, Inc.
HiberCell, Inc.
National Cancer Institute (NCI)
Zhejiang University
University of Florida
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
Genocea Biosciences, Inc.
AbbVie
AbbVie
Incyte Corporation
Incyte Corporation
Abramson Cancer Center at Penn Medicine
MedImmune LLC
National Institutes of Health Clinical Center (CC)
Pfizer
Merrimack Pharmaceuticals
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Northwestern University
Santa Maria Biotherapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)